The heme oxygenase/biliverdin reductase system: A potential drug target in Alzheimer's disease

Journal of Biological Regulators and Homeostatic Agents

Volumn 27, Issue 2 SUPPL., 2013, Pages 75-87

  Mancuso, C ^a   Santangelo, R ^a   Calabrese, V ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alzheimer's disease; Biliverdin reductase; Heme oxygenase; Nitric oxide; Oxidative stress

Indexed keywords

ATORVASTATIN; BILIVERDIN REDUCTASE; BIOLOGICAL MARKER; HEME OXYGENASE; HEME OXYGENASE 1; HEME OXYGENASE 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELLULAR STRESS RESPONSE; DRUG TARGETING; HUMAN; NEUROPATHOLOGY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84886783510     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37:517-554. (Pubitemid 27238886)
2. Mancuso C, Barone E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr Drug Metab 2009; 10:579-594.
3. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235:1043-1046. (Pubitemid 17049750)
4. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science 1993; 259:381-384. (Pubitemid 23055683)
5. Mancuso C, Navarra P, Preziosi P. Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem 2010; 113:563-575.
6. Mancuso C, Ragazzoni E, Tringali G, Liberale I, Preziosi P, Grossman A, Navarra P. Inhibition of heme oxygenase in the central nervous system potentiates endotoxin-induced vasopressin release in the rat. J Neuroimmunol 1999; 99:189-194 (Pubitemid 29518230)
7. Piantadosi CA. Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic Biol Med 2008; 45:562-569.
8. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions and pharmacological applications. Pharmacol Rev 2005; 57:585-630. (Pubitemid 43036442)
9. Stocker R, Glazer AN, Ames, BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987; 84:5918-5922. (Pubitemid 17130420)
10. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys 1998; 352:165-74. (Pubitemid 28368581)
11. Mancuso C, Bonsignore A, Capone C, Di Stasio E, Pani G. Albumin-bound bilirubin interacts with nitric oxide by a redox mechanism. Antioxid Redox Signal 2006; 8:487-494. (Pubitemid 43741317)
12. Mancuso C, Pani G, Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep 2006; 11:207-213. (Pubitemid 44741627)
13. Mancuso C, Bonsignore A, Di Stasio E, Mordente A, Motterlini R. Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide. Biochem Pharmacol 2003; 66:2355-2363. (Pubitemid 37456743)
14. Mancuso C, Scapagnini G, Curró D, Giuffrida Stella AM, De Marco C, Butterfield DA, Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007; 1:1107-1123. (Pubitemid 46846882)
15. Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opin Investig Drugs 2011; 20:1243-1261.
16. Mancuso C, Siciliano R, Barone E, Preziosi P. Natural substances and Alzheimer's disease: from preclinical studies to evidence based medicine. Biochim Biophys Acta 2012; 1822:616-624.
17. Calabrese V, Guagliano E, Sapienza M, Panebianco M, Calafato S, Puleo E, Pennisi G, Mancuso C, Butterfield DA, Stella AG. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem Res 2007; 32:757-773. (Pubitemid 46481305)
18. Calabrese V, Cornelius C, Trovato A, Cavallaro M, Mancuso C, Di Rienzo L,Condorelli D, De Lorenzo A, Calabrese EJ. The hormetic role of dietary antioxidants in free radical-related diseases. Curr Pharm Des 2010; 16:877-883.
19. Brambilla D, Mancuso C, Scuderi MR, Bosco P, Cantarella G, Lempereur L, Di Benedetto G, Pezzino S, Bernardini R. The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. Nutr J 2008; 7:29.
20. Takahashi S, Wang J, Rousseau DL, Ishikawa K, Yoshida T, Host JR, Ikeda-Saito M. Heme-heme oxygenase complex. Structure of the catalytic site and its implication for oxygen activation. J Biol Chem 1994; 269:1010-1014.
21. Maines MD. The heme oxygenase system and its functions in the brain. Cell Mol Biol 2000; 46:573-585.
22. Salinas M, Wang J, Rosa de Sagarra M, Martín D, Rojo AI, Martin-Perez J, Ortiz de Montellano PR, Cuadrado A. Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in vitro and in vivo. FEBS Lett 2004; 578: 90-94. (Pubitemid 39576106)
23. Maines MD. The heme oxygenase system: update 2005. Antioxid Redox Signal 2005; 7: 1761-1766. (Pubitemid 41768008)
24. Maines MD, Panahian N. The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions? Adv Exp Med Biol 2001; 502: 249-272. (Pubitemid 34234060)
25. Mancuso C. Heme oxygenase and its products in the nervous system. Antioxid Redox Signal 2004; 6:878-887. (Pubitemid 39237941)
26. Dwyer BE, Nishimura RN, Lu SY. Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody. Response to oxidative stress. Brain Res Mol Brain Res 1995; 30:37-47.
27. Zhuo M, Laitinen JT, Li XC, Hawkins RD. On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus. Learn Mem 1999; 6:63-76. (Pubitemid 29164549)
28. Bernabeu R, Princ F, de Stein ML, Fin C, Juknat AA, Batile A, Izquierdo I, Medina JH. Evidence for the involvement of hippocampal CO production in the acquisition and consolidation of inhibitory avoidance learning. Neuroreport 1995; 6:516-518.
29. Fin C, Schmitz PK, Da Silva RC, Bernabeu R, Medina JH, Izquierdo I. Intrahippocampal, but not intra-amygdala, infusion of an inhibitor of heme oxygenase causes retrograde amnesia in the rat. Eur J Pharmacol 1994; 271:227-229. (Pubitemid 24375870)
30. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993 Jan 7; 361:31-39. (Pubitemid 23020772)
31. Middei S, Roberto A, Berretta N, Panico MB, Lista S, Bernardi G, Mercuri NB, Ammassari-Teule M, Nisticò R. Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. Learn Mem 2010; 17:236-240.
32. Molinaro P, Viggiano D, Nisticò R, Sirabella R, Secondo A, Boscia F, Pannaccione A, Scorziello A, Mehdawy B, Sokolow S, Herchuelz A, Di Renzo GF, Annunziato L. Na+ -Ca2+ exchanger (NCX3) knock-out mice display an impairment in hippocampal long-term potentiation and spatial learning and memory. J Neurosci 2011; 31:7312-7321.
33. Balducci C, Mehdawy B, Mare L, Giuliani A, Lorenzini L, Sivilia S, Giardino L, Calzà L, Lanzillotta A, Sarnico I, Pizzi M, Usiello A, Viscomi AR, Ottonello S, Villetti G, Imbimbo BP, Nisticò G, Forloni G, Nisticò R.The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis 2011; 24:799-816.
34. Errico F, Nisticò R, Napolitano F, Mazzola C, Astone D, Pisapia T, Giustizieri M, D'Aniello A, Mercuri NB, Usiello A. Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging 2011; 32:2229-2243.
35. Errico F, Nisticò R, Napolitano F, Oliva AB, Romano R, Barbieri F, Florio T, Russo C, Mercuri NB, Usiello A. Persistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiol Aging 2011; 32:2061-2074.
36. La Rosa LR, Matrone C, Ferraina C, Panico MB, Piccirilli S, Di Certo MG, Strimpakos G, Mercuri NB, Calissano P, D'Amelio M, Nisticò R. Age-related changes of hippocampal synaptic plasticity in ABPP-null mice are restored by NGF through p75NTR. J Alzheimers Dis 2013; 33:265-272.
37. Nisticò R, Mango D, Mandolesi G, Piccinin S, Berretta N, Pignatelli M, Feligioni M, Musella A, Gentile A, Mori F, Bernardi G, Nicoletti F, Mercuri NB, Centonze D. Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One 2013; 8:e54666.
38. Pignatelli M, Vollmayr B, Richter SH, Middei S, Matrisciano F, Molinaro G, Nasca C, Battaglia G, Ammassari-Teule M, Feligioni M, Nisticò R, Nicoletti F, Gass P. Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats. Neuropharmacology 2013; 66:339-347.
39. Pignatelli M, Feligioni M, Piccinin S, Molinaro G, Nicoletti F, Nisticò R.Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders. Curr Pharm Des. 2013b Feb 13. [Epub ahead of print]
40. Gibbs PE, Tudor C, Maines MD. Biliverdin reductase: more than a namesake - the reductase, its peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front Pharmacol 2012; 3:31.
41. Kapitulnik J, Maines MD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 2009; 30:129-137.
42. Maines MD. New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 2005; 20:382-389. (Pubitemid 41812421)
43. Maines MD, Trakshel GM. Purification and characterization of human biliverdin reductase. Arch Biochem Biophys 1993; 300:320-326. (Pubitemid 23225753)
44. Salim M, Brown-Kipphut BA, Maines MD. Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. J Biol Chem 2001; 276:10929-10934. (Pubitemid 38089271)
45. Barone E, Trombino S, Cassano R, Sgambato A, De Paola B, Di Stasio E, Picci N, Preziosi P, Mancuso C. Characterization of the S-denitrosylating activity of bilirubin. J Cell Mol Med 2009; 13:2365-2375.
46. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 2004; 66:773-779. (Pubitemid 39319447)
47. Maines MD, Ewing JF, Huang TJ, Panahian N. Nuclear localization of biliverdin reductase in the rat kidney: response to nephrotoxins that induce heme oxygenase-1. J Pharmacol Exp Ther 2001; 296:1091-1097. (Pubitemid 32187386)
48. Ewing JF, Weber CM, Maines MD. Biliverdin reductase is heat resistant and coexpressed with constitutive and heat shock forms of heme oxygenase in brain. J Neurochem 1993; 6:1015-1023. (Pubitemid 23241240)
49. Ewing JF, Maines MD. Immunohistochemical localization of biliverdin reductase in rat brain: age related expression of protein and transcript. Brain Res 1995; 672:29-41.
50. Maines MD, Miralem T, Lerner-Marmarosh N, Shen J, Gibbs PE. Human biliverdin reductase, a previously unknown activator of protein kinase C betaII. J Biol Chem 2007; 282:8110-8122. (Pubitemid 47093608)
51. Lerner-Marmarosh N, Miralem T, Gibbs PE, Maines MD. Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc Natl Acad Sci U S A 2008; 105: 6870-6875. (Pubitemid 351754497)
52. Mancuso C, Capone C, Ranieri SC, Fusco S, Calabrese V, Eboli ML, Preziosi P, Galeotti T, Pani G. Bilirubin as an endogenous modulator of neurotrophin redox signaling. J Neurosci Res 2008; 86:2235-2249.
53. Tudor C, Lerner-Marmarosh N, Engelborghs Y, Gibbs PE, Maines MD. Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem J 2008; 413:405-416
54. Wegiel B, Baty CJ, Gallo D, Csizmadia E, Scott JR, Akhavan A, Chin BY, Kaczmarek E, Alam J, Bach FH, Zuckerbraun BS, Otterbein LE. Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem 2009; 284:21369-21378.
55. Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007; 114:261-277. (Pubitemid 46844843)
56. Zheng WH, Kar S, Doré S, Quirion R. Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. J Neural Transm 2000; Suppl 60: 261-272. (Pubitemid 32037198)
57. Lerner-Marmarosh N, Shen J, Torno MD, Kravets A, Hu Z, Maines MD. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Natl Acad Sci U S A 2005; 102:7109-7114. (Pubitemid 40696342)
58. Santangelo R, Mancuso C, Marchetti S, Di Stasio E, Pani G, Fadda G. Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro. Front Pharmacol 2012; 3:36.
59. Nisticò R, Collingridge GL. The synaptic basis of Alzheimer's disease. Eur J Neurodeg Dis. 2012; 1:21-33.
60. Fern CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366:2112-2117. (Pubitemid 41797645)
61. Mayeux R. Clinical practice. Early Alzheimer's disease. N Engl J Med. 2010; 362:2194-2201.
62. Seripa D, Panza F, Franceschi M, D'Onofrio G; Solfrizzi V, Dallapiccola B, Pilotto A. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Res Rev 2009; 8:214-236.
63. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23:213-227.
64. Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging 2011; 32:778-790.
65. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362:329-344.
66. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007; 43:658-677. (Pubitemid 47102132)
67. Lee JH, Won SM, Suh J, Son SJ, Moon GJ, Park UJ, Gwaq BJ. Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice. Exp Mol Med 2010; 42:386-394.
68. Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida Stella AM, Schapira T, Dinkova Kostova AT, Rizzarelli E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 2008; 33:2444-2471.
69. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377:1019-1031.
70. Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, Perluigi M, Sultana R, Butterfield DA. Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease. Neurotox Res 2012; 22:220-230.
71. Carrard G, Bulteau AL, Petropoulos I, Friguet B. Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 2002; 34:1461-1474. (Pubitemid 35245402)
72. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem 2002; 83:176-185.
73. Sultana R, Butterfield DA. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr 2009; 41:441-446.
74. Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009; 41:425-431.
75. Rhein V, Eckert A. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function - role of glucose metabolism and insulin signalling. Arch Physiol Biochem 2007; 113:131-141. (Pubitemid 47547386)
76. Bayer TA, Schäfer S, Breyhan H, Wirths O, Treiber C, Multhaup G. A vicious circle: role of oxidative stress, intraneuronal Abeta and Cu in Alzheimer's disease. Clin Neuropathol 2006; 25:163-171. (Pubitemid 44047901)
77. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, St Clair DK. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 2006; 168:1608-1618.
78. Kinouchi H, Kamii H, Mikawa S, Epstein CJ, Yoshimoto T, Chan PH. Role of superoxide dismutase in ischemic brain injury: a study using SOD-1 transgenic mice. Cell Mol Neurobiol 1998; 18:609-620. (Pubitemid 29012940)
79. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radie Biol Med 1997; 23:134-147. (Pubitemid 27217017)
80. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 2007; 8:766-775. (Pubitemid 47462116)
81. Esiri MM, Pearson RC, Steele JE, Bowen DM, Powell TP. A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1990; 53:161-165. (Pubitemid 20067665)
82. Sajan FD, Martiniuk F, Marcus DL, Frey WH 2nd, Hite R, Bordayo EZ, Freedman ML. Apoptotic gene expression in Alzheimer's disease hippocampal tissue. Am J Alzheimers Dis Other Demen 2007; 22:319-328. (Pubitemid 47330152)
83. Panahian N, Yoshiura M, and Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem 1999; 72:1187-1203. (Pubitemid 29085035)
84. Takeda A, Perry G, Abraham NG, Dwyer BE, Kutty RK, Laitinen JT, Petersen RB, and Smith MA. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J Biol Chem 2000; 275:5395-5399. (Pubitemid 30115170)
85. Hui Y, Wang D, Li W, Zhang L, Jin J, Ma N, Zhou L, Nakajima O, Zhao W, Gao X. Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. J Alzheimers Dis 2011; 26:299-313.
86. Vaccari A, Ruiu S, Saba P, Fà M, Cagiano R, Coluccia A, Mereu G, Steardo L, Tattoli M, Trabace L, Cuomo V. Prenatal low-level exposure to CO alters postnatal development of hippocampal nitric oxide synthase and haem-oxygenase activities in rats. Int J Neuropsychopharmacol 2001; 4:219-222. (Pubitemid 34101517)
87. Mereu G, Cammalleri M, Fà M, Francesconi W, Saba P, Tattoli M, Trabace L, Vaccari A, Cuomo V. Prenatal exposure to a low concentration of carbon monoxide disrupts hippocampal long-term potentiation in rat offspring. J Pharmacol Exp Ther 2000; 294:728-734. (Pubitemid 30490851)
88. Poss KD, Thomas MJ, Ebralidze AK, O'Dell TJ, Tonegawa S. Hippocampal long-term potentiation is normal in heme oxygenase-2 mutant mice. Neuron; 15:867-873.
89. Toyoda M, Saito H, Matsuki N. Nitric oxide but not carbon monoxide is involved in spatial learning of mice. Jpn J Pharmacol 1996; 71:205-211. (Pubitemid 26264264)
90. Koeppen AH, Dickson AC. Neuroprotection in intracerebral hemorrhage with tin-protoporphyrin. Ann Neurol 1999; 46:938.
91. Schipper HM, Bernier L, Mehindate K, and Frankel D. Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore. J Neurochem 1999; 72:1802-1811. (Pubitemid 29185982)
92. Schipper HM. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp Gerontol 2000; 35:821-830.
93. Minotti G. Sources and role of iron in lipid peroxidation. Chem Res Toxicol 1993; 6:134-146. (Pubitemid 23086897)
94. Chiueh CC. Iron overload, oxidative stress, and axonal dystrophy in brain disorders. Pediatr Neurol 2001; 25:138-147. (Pubitemid 32830163)
95. Goldstein L, Teng ZP, Zeserson E, Patel M, Regan RF. Hemin induces an iron-dependent, oxidative injury to human neuron-like cells. J Neurosci Res 2003; 73:113-121. (Pubitemid 36791376)
96. Schipper HM, Gupta A, Szarek WA. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr Alzheimer Res 2009; 6:424-430.
97. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, Butterfield DA. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med; 52:2292-2301.
98. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, Perluigi M, Mancuso C, Butterfield DA. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis 2011; 25:623-633.
99. Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, Perluigi M, Mancuso C, Butterfield DA. Biliverdin reductase - a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta 2011; 1812:480-487.
100. Di Domenico F, Barone E, Mancuso C, Perluigi M, Cocciolo A, Mecocci P, Butterfield DA, Coccia R. HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease. J Alzheimers Dis 2012; 32:277-289.
101. Nisticò R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G. Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol Neurobiol; 46:572-587.
102. Massoud F, Léger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry; 56:579-588.
103. Siciliano R, Barone E, Calabrese V, Rispoli V, Butterfield DA, Mancuso C. Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge. CNS Neurol Disord Drug Targets 2011; 10:766-776.
104. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005;2:155-165. (Pubitemid 40862876)
105. Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J Clin Pharmacol 2006; 46(7 Suppl 1):8S-16S. (Pubitemid 43882807)
106. Cosman KM, Boyle LL, Porsteinsson AP. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother 2007; 8:203-214. (Pubitemid 46206622)
107. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010; 16:235-245.
108. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; (1):CD005593.
109. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009; (2):CD001191.
110. Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 2011;64:180-186.
111. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, Mancuso C, Head E. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol 2012; 15:981-987.
112. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem 2012; 120:135-146.